193 related articles for article (PubMed ID: 10859719)
1. What have We learned from ESPRIT? What will we learn from TARGET?
Ferguson JJ
J Invasive Cardiol; 2000 Jun; 12(6):317-9. PubMed ID: 10859719
[No Abstract] [Full Text] [Related]
2. [Antithrombotic treatment of acute coronary syndromes without ST-segment elevation].
Radke PW; Schunkert H
Dtsch Med Wochenschr; 2006 Nov; 131(47 Suppl 7):S204-7. PubMed ID: 17109249
[No Abstract] [Full Text] [Related]
3. [New antiplatelet agents].
Diez-Ewald
Invest Clin; 2000 Sep; 41(3):147-8. PubMed ID: 11029831
[No Abstract] [Full Text] [Related]
4. [Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].
Araujo R; Agustí A
Med Clin (Barc); 2000 Oct; 115(11):435-7. PubMed ID: 11093849
[No Abstract] [Full Text] [Related]
5. The TARGET trial: hit or miss?
Moliterno DJ; Topol EJ
Eur Heart J; 2002 Jun; 23(11):835-7. PubMed ID: 12042001
[No Abstract] [Full Text] [Related]
6. [Platelet antiaggregation treatment in the aftermath of GUSTO IV, TARGET, TACTICS, and CURE trials].
Bassand JP
Rev Esp Cardiol; 2002 Jul; 55(7):697-702. PubMed ID: 12113695
[TBL] [Abstract][Full Text] [Related]
7. The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?
Brener SJ
J Am Coll Cardiol; 2009 May; 53(18):1674-6. PubMed ID: 19406343
[No Abstract] [Full Text] [Related]
8. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Roe MT; Sapp SK; Lincoff AM
Cleve Clin J Med; 2000 Feb; 67(2):131-40. PubMed ID: 10680279
[TBL] [Abstract][Full Text] [Related]
9. [GP IIb/IIIa receptor prevention medicine].
Goto S
Nihon Rinsho; 2003 Apr; 61 Suppl 4():457-61. PubMed ID: 12735015
[No Abstract] [Full Text] [Related]
10. Appropriate antiplatelet and antithrombotic therapy in patients with acute coronary syndromes: recent updates to the ACC/AHA guidelines.
Mehta SR;
J Invasive Cardiol; 2002 Dec; 14 Suppl E():27E-34E; quiz 35E. PubMed ID: 12668860
[TBL] [Abstract][Full Text] [Related]
11. ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy.
Boden WE; Hoekstra J; Miller CD
Am J Emerg Med; 2008 Feb; 26(2):212-20. PubMed ID: 18272105
[TBL] [Abstract][Full Text] [Related]
12. [Inhibitors of platelet glycoprotein IIb-IIIa in cardiology].
Obradović S; Gligić B; Djordjević D; Jovicić A; Romanović R; Ratković N; Dincić D; Orozović V; Nikolić G
Vojnosanit Pregl; 2001; 58(1):65-72. PubMed ID: 11419288
[No Abstract] [Full Text] [Related]
13. [New antiaggregants and their importance for the practitioner].
Tsakiris DA
Ther Umsch; 2003 Jan; 60(1):24-6. PubMed ID: 12638474
[TBL] [Abstract][Full Text] [Related]
14. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban).
Assali AR; Salloum J; Sdringola S; Moustapha A; Ghani M; Hale S; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR
Am J Cardiol; 2001 Oct; 88(8):884-6, A6. PubMed ID: 11676953
[No Abstract] [Full Text] [Related]
15. Treatment of unstable angina: the role of platelet inhibitors and anticoagulants.
Cohen M
J Invasive Cardiol; 1999 Mar; 11(3):147-59. PubMed ID: 10745504
[TBL] [Abstract][Full Text] [Related]
16. GP IIb/IIIa inhibitors: an evidence-based approach to their use.
Med Manag Netw; 1999 Mar; 7(3):5-9. PubMed ID: 10346546
[No Abstract] [Full Text] [Related]
17. [Spleen rupture in myocardial infarction after administration of GP IIb-IIIa-antagonists].
Feldmann C; Deutsch HJ
Dtsch Med Wochenschr; 2005 Jan; 130(1-2):29-30. PubMed ID: 15619171
[No Abstract] [Full Text] [Related]
18. Management of acute coronary syndromes.
Schulman SP; Fessler HE
Am J Respir Crit Care Med; 2001 Sep; 164(6):917-22. PubMed ID: 11587971
[No Abstract] [Full Text] [Related]
19. Upstream/downstream glycoprotein IIb/IIIa in non-ST-segment elevation myocardial infarction.
Ben-Yehuda O
J Am Coll Cardiol; 2006 Feb; 47(3):538-40. PubMed ID: 16458132
[No Abstract] [Full Text] [Related]
20. Ischemic coronary syndromes and SVG Interventions--do 2b/3a inhibitors miss the target?
Topaz O
Catheter Cardiovasc Interv; 2007 Apr; 69(5):630-1. PubMed ID: 17377986
[No Abstract] [Full Text] [Related]
[Next] [New Search]
